These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
446 related articles for article (PubMed ID: 25239590)
1. Prucalopride is no more effective than placebo for children with functional constipation. Mugie SM; Korczowski B; Bodi P; Green A; Kerstens R; Ausma J; Ruth M; Levine A; Benninga MA Gastroenterology; 2014 Dec; 147(6):1285-95.e1. PubMed ID: 25239590 [TBL] [Abstract][Full Text] [Related]
2. A placebo-controlled trial of prucalopride for severe chronic constipation. Camilleri M; Kerstens R; Rykx A; Vandeplassche L N Engl J Med; 2008 May; 358(22):2344-54. PubMed ID: 18509121 [TBL] [Abstract][Full Text] [Related]
3. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study. Quigley EM; Vandeplassche L; Kerstens R; Ausma J Aliment Pharmacol Ther; 2009 Feb; 29(3):315-28. PubMed ID: 19035970 [TBL] [Abstract][Full Text] [Related]
4. Oral prucalopride in children with functional constipation. Winter HS; Di Lorenzo C; Benninga MA; Gilger MA; Kearns GL; Hyman PE; Vandeplassche L; Ausma J; Hoppenbrouwers M J Pediatr Gastroenterol Nutr; 2013 Aug; 57(2):197-203. PubMed ID: 23535761 [TBL] [Abstract][Full Text] [Related]
5. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Tack J; van Outryve M; Beyens G; Kerstens R; Vandeplassche L Gut; 2009 Mar; 58(3):357-65. PubMed ID: 18987031 [TBL] [Abstract][Full Text] [Related]
6. Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation -- a comparison in a controlled environment. Cinca R; Chera D; Gruss HJ; Halphen M Aliment Pharmacol Ther; 2013 May; 37(9):876-86. PubMed ID: 23480216 [TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride. Piessevaux H; Corazziari E; Rey E; Simren M; Wiechowska-Kozlowska A; Kerstens R; Cools M; Barrett K; Levine A Neurogastroenterol Motil; 2015 Jun; 27(6):805-15. PubMed ID: 25808103 [TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation. Yiannakou Y; Piessevaux H; Bouchoucha M; Schiefke I; Filip R; Gabalec L; Dina I; Stephenson D; Kerstens R; Etherson K; Levine A Am J Gastroenterol; 2015 May; 110(5):741-8. PubMed ID: 25869393 [TBL] [Abstract][Full Text] [Related]
9. Treating constipation with prucalopride: one size does not fit all. Nurko S; Saps M Gastroenterology; 2014 Dec; 147(6):1214-6. PubMed ID: 25457845 [No Abstract] [Full Text] [Related]
10. A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Shin A; Acosta A; Camilleri M; Boldingh A; Burton D; Ryks M; Rhoten D; Zinsmeister AR Clin Gastroenterol Hepatol; 2015 Apr; 13(4):701-8.e1. PubMed ID: 25148765 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Krogh K; Jensen MB; Gandrup P; Laurberg S; Nilsson J; Kerstens R; De Pauw M Scand J Gastroenterol; 2002 Apr; 37(4):431-6. PubMed ID: 11989834 [TBL] [Abstract][Full Text] [Related]
13. Association between health-related quality of life and symptoms in patients with chronic constipation: an integrated analysis of three phase 3 trials of prucalopride. Tack J; Camilleri M; Dubois D; Vandeplassche L; Joseph A; Kerstens R Neurogastroenterol Motil; 2015 Mar; 27(3):397-405. PubMed ID: 25581251 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials. Camilleri M; Piessevaux H; Yiannakou Y; Tack J; Kerstens R; Quigley EMM; Ke M; Da Silva S; Levine A Dig Dis Sci; 2016 Aug; 61(8):2357-2372. PubMed ID: 27056037 [TBL] [Abstract][Full Text] [Related]
15. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Shin A; Camilleri M; Kolar G; Erwin P; West CP; Murad MH Aliment Pharmacol Ther; 2014 Feb; 39(3):239-53. PubMed ID: 24308797 [TBL] [Abstract][Full Text] [Related]
16. Prucalopride: a review of its use in the management of chronic constipation. Keating GM Drugs; 2013 Nov; 73(17):1935-50. PubMed ID: 24194435 [TBL] [Abstract][Full Text] [Related]
18. Prucalopride succinate for the treatment of constipation: an update. Bassotti G; Gambaccini D; Bellini M Expert Rev Gastroenterol Hepatol; 2016; 10(3):291-300. PubMed ID: 26647167 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Sloots CE; Rykx A; Cools M; Kerstens R; De Pauw M Dig Dis Sci; 2010 Oct; 55(10):2912-21. PubMed ID: 20428949 [TBL] [Abstract][Full Text] [Related]
20. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Sloots CE; Poen AC; Kerstens R; Stevens M; De Pauw M; Van Oene JC; Meuwissen SG; Felt-Bersma RJ Aliment Pharmacol Ther; 2002 Apr; 16(4):759-67. PubMed ID: 11929394 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]